Silk-Elastinlike Protein Polymer Liquid Chemoembolic for Localized Release of Doxorubicin and Sorafenib
- 29 June 2016
- journal article
- research article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 13 (8), 2736-2748
- https://doi.org/10.1021/acs.molpharmaceut.6b00325
Abstract
Locoregional therapies for cancer are minimally invasive procedures in which the treatment is administered directly into cancerous tissue. Transarterial chemoembolization (TACE) is used to treat intermediate stage hepatocellular carcinoma (HCC). TACE uses an embolic material to block blood flow while coadministering a chemotherapeutic to the neoplastic tissue. Liquid embolics capable of drug loading are at the forefront of development as they allow for deeper permeation of tumor vasculature, increase neoplasm exposure to therapeutics, and resist revascularization by occupying both large and small diameter vessels. In this work, two chemotherapeutics used in the treatment of HCC, doxorubicin and sorafenib, were incorporated into the in situ gelling liquid embolic composed of a silk-elastinlike protein polymer (SELP-815 K). The base forms of the drugs had no significant effect on the viscosity, the gelation kinetics, and the gel stiffness of the SELP: all properties essential for the successful performance of an injectable liquid embolic. In vitro release studies indicated that the SELP liquid embolic delivered doxorubicin and sorafenib, either alone or in combination, at therapeutically relevant concentrations for a minimum of 14 and 30 days, respectively.Keywords
Funding Information
- National Cancer Institute (F30 CA176922, R01 CA107621, R41 CA168123)
- Division of Graduate Education (1256065)
This publication has 38 references indexed in Scilit:
- Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical ResultsRadiology, 2015
- Transarterial Chemoembolization (TACE) plus Sorafenib Versus TACE for Intermediate or Advanced Stage Hepatocellular Carcinoma: A Meta-AnalysisPLOS ONE, 2014
- Epidemiology of hepatocellular carcinoma in the United States: Where are we? Where do we go?Hepatology, 2014
- Phase II Trial of Sorafenib Combined With Concurrent Transarterial Chemoembolization With Drug-Eluting Beads for Hepatocellular CarcinomaJournal of Clinical Oncology, 2011
- Hepatocellular CarcinomaNew England Journal of Medicine, 2011
- Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinomaEuropean Journal Of Cancer, 2011
- Management of hepatocellular carcinoma: An updateHepatology, 2011
- Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular CarcinomaJAMA, 2010
- Loco-regional treatment of hepatocellular carcinomaHepatology, 2010
- Liver Anatomy: Microcirculation of the LiverSeminars in Interventional Radiology, 2008